Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
about
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyVandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomitingChemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).Higher dose of palonosetron versus lower dose of palonosetron plus droperidol to prevent postoperative nausea and vomiting after eye enucleation and orbital hydroxyapatite implant surgery: a randomized, double-blind trialDaily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Palonosetron: A novel approach to control postoperative nausea and vomiting in day care surgery.Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults5-HT3 receptor antagonists for prevention of late acute-onset emesis.Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomitingAprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Antiemetic therapy in cancer: an update.Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.Clinical practice guidelines on antiemetics in oncology.Emerging drugs for chemotherapy-induced emesis.New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron.Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery.Palonosetron as an anti-emetic and anti-nausea agent in oncology.Management of postoperative nausea and vomiting: focus on palonosetronEffect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: a single-blind, randomized, controlled trial.Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron.Selective use of vandetanib in the treatment of thyroid cancer.
P2860
Q26783229-52326ADB-6E66-4690-BA67-BC7AB2D3377FQ27692050-D8FE6DDC-7329-47CE-8E5D-44459EFF6D22Q28280032-6BEA3B19-D775-47CB-AB60-E7727A58619CQ30436557-D193C267-3313-4CA1-886F-E111ABCEFFBDQ33713958-626A90A8-0ACB-4081-9A09-32E5234AD226Q34289628-79840A6C-69B7-4465-87CB-89EA1588407CQ34327488-3D2F5101-F603-4540-9C9E-DA5B6B502D4CQ34418467-87D90929-155F-45B2-B961-175BC0338F24Q34588516-7F05299E-B3B0-4676-9542-1B11A73A7873Q34775395-6C548772-4279-49D7-A066-6F523AEECE33Q35006180-05D8AF5B-BC49-4E32-9C1E-C46FB0BE9060Q35107994-C751DD23-E3E1-4AF6-BF31-DF0EEF12E0C6Q35208781-F3D8B8DE-F225-487A-9BA6-5FD9D6FC0469Q35584439-71D46C50-075D-4B62-8CE3-FCE277BE1859Q35865448-5FB4CAEA-88E2-4637-8D5A-9EB2624D3EEDQ35870991-6DD99BD9-D192-4780-B560-CADDF55DC307Q35918427-B65C29DE-68F9-4625-B94D-47968EA0B063Q36222061-A24938F0-E114-420C-BFC3-41A16926182AQ36276557-79637151-6A14-46D0-AFC2-ADD30B8EDF86Q36334870-139A7B92-0ED4-4098-8B06-67967780D145Q36407422-C58F7783-96C1-46BA-A5F9-7C994C57C684Q36572642-267E70EB-3DEE-4233-9D75-4154D1501676Q36575446-3E52C4FC-A32B-4C53-9D1F-B8996D494D81Q36616499-FA31B631-76B2-4CB2-BA29-6B59694DC566Q36636930-983710CB-EB1E-4B14-8B6D-B9D13957489AQ36663660-60BCDE26-043C-45D2-A39E-080C004CD46DQ37230293-2DAA0C83-563F-46FD-BCE1-9AABE0D14F5EQ37576243-B49CB5B0-77E4-486E-AEE1-C8CD9DC9BA6DQ37636028-2E5B3072-DFBE-422C-BEE7-B2CD533E481CQ37687368-FCB5ED0A-E789-4F30-8FD6-1BD7BA8A7B03Q37760068-5134F46F-08A3-47AD-AF01-BE46CE7AADAAQ37771953-F18723E2-AABB-4AED-A291-4772EE6FB526Q37783929-B45EBBCF-46E0-44DA-AA8A-3E5D88FC61F4Q38004016-399AEE23-D578-4D8E-B688-E15FE1116B7FQ38132238-DB776DEA-5C6C-4CC8-815F-7AF7285CDC24Q38208999-9E747EF5-C468-4747-A8BC-8C7F72DE05D0Q38246665-CDCC09B3-ECE6-4845-9439-7F8F704A0E03Q38260952-D4E36AA5-5EE1-43B9-9D14-602296ED8A57Q38497106-E6B98549-3460-4C4C-A2DE-63F1222061EFQ38546474-0A82988F-A4B0-469D-8610-65A249AE364B
P2860
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@en
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@nl
type
label
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@en
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@nl
prefLabel
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@en
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@nl
P2093
P356
P1433
P1476
Efficacy, safety and pharmacok ...... a dose-ranging clinical study.
@en
P2093
A Macciocchi
P A Cornett
P Eisenberg
P304
P356
10.1093/ANNONC/MDH047
P577
2004-02-01T00:00:00Z